Business
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Portugal With Azevedos Indústria Farmacêutica, S.A
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Portugal With Azevedos Indústria Farmacêutica, S.A.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n OTTAWA, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the signing of a definitive agreement with Azevedos Indústria Farmacêutica, S.A. (Azevedos) for the marketing and distribution of CAUMZTM (PPP011) in Portugal.   “Portugal has taken an innovative approach in its opioid battle, and Azevedos, the oldest pharmaceutical brand name in Portugal, is one of the leaders in the fight against opioid abuse. We are thrilled to partner with this forward thinking company and share in its commitment to bringing effective alternatives to opioids,” said Guy Chamberland, Ph.D., CEO and Chief Regulatory Officer of Tetra Bio-Pharma. “Azevedos is a global company with distribution capabilities throughout Europe, a state of the art manufacturing facility in Portugal and facilities in Mozambique and Tunisia. With the potential to manufacture a number of our prescription drug products for commercial launch in the European market, we are excited and look forward to further building this relationship with Azevedos.” Under the terms of the agreement, Tetra will receive milestone payments and profit sharing on all sales of CAUMZTM in Portugal.  In return, Azevedos will be responsible for registering the product, manufacturing, as well as all marketing and distribution in Portugal.  About Tetra Bio-PharmaTetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com Source: Tetra Bio-Pha...